-
前列腺癌是男性最常见的恶性肿瘤之一,在发达国家其发病率位居男性恶性肿瘤的首位;病死率仅次于肺癌和结直肠癌,位居男性恶性肿瘤的第3位[1]。前列腺癌在某种意义上是一种异质性疾病,尽管该病在某些患者中可能处于休眠状态,但在有些患者中可以迅速发展[2]。研究结果显示,前列腺癌抗雄激素治疗后1~5个月原发灶和转移灶的18F-FDG摄取减少,这与血清前列腺特异性抗原水平下降和CT上病变大小减小一致[3-4]。 目前, 18F-FDG是应用最为广泛的糖代谢正电子显像剂[5],在多种肿瘤的探测、鉴别诊断及分期上具有独特优势。由于前列腺癌的生物学和组织学特性具有多样化的特点,其对18F-FDG的摄取也表现出不同程度的差异。国内文献报道,18F-FDG PET/CT对于前列腺癌的检出率仅为61%[6]。故目前对前列腺癌的诊断仍存在争议,临床上正常前列腺18F-FDG PET/CT摄取异常的现象并不少见[7]。目前国内对于正常前列腺生理性摄取18F-FDG的相关研究相对较少。因此,我们通过分析正常前列腺18F-FDG PET/CT代谢显像的增龄变化,旨在构建前列腺葡萄糖代谢正常值评价体系以及对18F-FDG PET/CT在前列腺癌中的精确诊断提供对比参照。
-
181例患者的前列腺最大横径为3.4~6.5(4.66±0.59) cm,SUVmax为1.0~4.2(2.44±0.49),SUVmean为0.7~3.4( 1.97±0.44),CTmean为25~46( 34.48±3.72) HU。前列腺最大横径与患者年龄呈正相关(r=0.465,P<0.001),CTmean随患者年龄的增长而增加,两者呈极弱相关性或无相关性(r=0.126,P=0.091);而SUVmax、SUVmean与患者年龄、前列腺最大横径无相关性(r=0.047、0.071、0.040、0.035,均P>0.05)(表1,图1)。不同年龄段的各组患者的最大横径均值间的差异有统计学意义(F=16.278,P<0.001),而SUVmax、SUVmean、CTmean均值间的差异均无统计学意义(F=0.485、1.114、1.025,均P>0.05)(表2)。
因变量 自变量 截距 斜率 r值 P值 最大横径 年龄 3.52 0.019 0.465 0.000 SUVmax 年龄 2.34 0.002 0.047 0.534 SUVmean 年龄 1.85 0.002 0.071 0.344 CTmean 年龄 32.53 0.032 0.126 0.091 SUVmax 最大横径 2.28 0.033 0.040 0.591 SUVmean 最大横径 1.86 0.026 0.035 0.644 CTmean 最大横径 33.97 0.111 0.018 0.814 SUVmean CTmean 2.13 −0.004 −0.038 0.612 注:表中,FDG:氟脱氧葡萄糖;PET:正电子发射断层显像术;CT:计算机体层摄影术;SUVmax:最大标准化摄取值;SUVmean:平均标准化摄取值;CTmean:平均CT值 表 1 181例非前列腺癌患者的18F-FDG PET/CT参数及患者 年龄的相关性分析
Table 1. Correlation analysis among 18F-FDG PET/CT parameters, and patient age of 181 non prostate cancer
图 1 非前列腺癌患者18F-FDG PET/CT参数及患者年龄相关性分析的散点图及线性回归趋势线
Figure 1. Scatter plot and fit straight line of correlation analysis among 18F-FDG PET/CT parameters, and age of non prostate cancer
年龄段 例数 最大横径(cm) SUVmax SUVmean CTmean (HU) 19~39岁 16 4.04±0.27 2.48±0.65 2.03±0.51 33.25±3.59 40~59岁 57 4.52±0.53 2.38±0.50 1.90±0.44 34.19±3.76 60~79岁 94 4.77±0.54 2.46±0.47 2.00±0.42 34.76±3.80 80~99岁 14 5.24±0.65 2.48±0.42 2.05±0.41 35.29±2.97 F值 16.278 0.485 1.114 1.025 P值 0.000 0.693 0.345 0.383 LSD-t值 3.106 0.352 0.835 0.933 P值 0.001 0.772 0.442 0.355 注:表中,FDG:氟脱氧葡萄糖;PET:正电子发射断层显像术;CT:计算机体层摄影术;SUVmax:最大标准化摄取值;SUVmean:平均标准化摄取值;CTmean:平均CT值 表 2 181例不同年龄段非前列腺癌患者的18F-FDG PET/CT 的参数比较(
)$\bar x \pm s $ Table 2. Comparison of 18F-FDG PET/CT parameters of 181 non prostate cancer in all age groups (
)$\bar x \pm s $
正常前列腺18F-FDG PET/CT代谢显像增龄变化的研究
Study on 18F-FDG PET/CT metabolic imaging of normal prostate with increasing age
-
摘要:
目的 探讨18F-氟脱氧葡萄糖(FDG) PET/CT显像中正常前列腺标准化摄取值(SUV)、CT值、PET/CT横断位最大层面测量的前列腺左右径(简称最大横径)和患者年龄之间的关系。 方法 回顾性分析2018年6月至2019年2月在安徽医科大学第二附属医院行18F-FDG PET/CT显像的非前列腺癌男性患者181例,年龄19~94(60.6±14.5)岁。将患者按年龄段分为4组:19~39岁16例、40~59岁57例、60~79岁94例、80~99岁14例。采用勾画感兴趣区(ROI)的方法测量各组患者前列腺18F-FDG最大标准化摄取值(SUVmax)、平均标准化摄取值(SUVmean)和平均CT值(CTmean),并在前列腺横断位最大层面测量前列腺最大横径。采用Pearson相关性分析、散点图和线性回归趋势线分析前列腺最大横径、SUVmax、SUVmean、CTmean和年龄之间的相关性,采用单因素方差分析及LSD-t检验对各组患者相关参数的均值进行多重比较。 结果 181例患者的前列腺最大横径为3.4~6.5(4.66±0.59) cm,SUVmax为1.0~4.2(2.44±0.49),SUVmean为0.7~3.4(1.97±0.44),CTmean为25~46(34.48±3.72) HU。前列腺最大横径与患者年龄呈正相关(r=0.465,P<0.001);前列腺SUVmax、SUVmean与患者年龄、前列腺最大横径无相关性(r=0.047、0.071、0.040、0.035,均P>0.05);前列腺CTmean随患者年龄的增长而增加,两者呈极弱相关性或无相关(r=0.126,P=0.091)。不同年龄段的各组患者的前列腺最大横径分别为(4.04±0.27)、(4.52±0.53)、(4.77±0.54)、(5.24±0.65)cm;SUVmax分别为(2.48±0.65)、(2.38±0.50)、(2.46±0.47)和(2.48±0.42);SUVmean分别为(2.03±0.51)、(1.90±0.44)、(2.00±0.42)和(2.05±0.41);CTmean分别为(33.25±3.59)、(34.19±3.76)、(34.76±3.80)、(35.29±2.97) HU。不同年龄段的各组患者前列腺最大横径之间的差异有统计学意义(F=16.278,P<0.001),而SUVmax、SUVmean和CTmean之间的差异均无统计学意义。 结论 前列腺最大横径随着患者年龄的增长而增加,但患者年龄不会显著影响前列腺的糖代谢和CT密度。 -
关键词:
- 前列腺 /
- 年龄组 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 氟脱氧葡萄糖F18 /
- 标准化摄取值
Abstract:Objective To investigate the correlations among standardized uptake value (SUV), CT value, maximum transverse diameter of normal prostate, and patient age through 18F-fluorodeoxyglucose (FDG) PET/CT. Methods Retrospective analysis of 181 male patients aged 19–94 (60.6±14.5) years who underwent 18F-FDG PET/CT in the Second Hospital of Anhui Medical University from June 2018 to February 2019 was performed. The patients were divided into four groups by age group (19–39 years, 16 cases; 40–59 years, 57 cases; 60–79 years, 94 cases; and 80–99 years, 14 cases). The maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and mean CT value (CTmean) of prostate 18F-FDG were measured through a delineated region of interest method, and the maximum transverse diameter of the prostate was measured at the maximum transverse plane of the prostate. SPSS 16.0 statistical software was used in analyzing the correlations among the maximum transverse diameter of the prostate, SUVmax, SUVmean, CTmean, and age on the basis of the Pearson correlation coefficient, scatter plot, and linear regression trend line. One-way ANOVA and LSD-t test were used for each parameter. Results The maximum transverse diameter of the normal prostate was 3.4–6.5(4.66±0.59) cm, SUVmax was 1.0–4.2 (2.44±0.49), SUVmean was 0.7–3.4(1.97±0.44), CTmean was 25–46(34.5±3.72) HU. The maximum transverse diameter of the prostate was positively correlated with age (r=0.465, P<0.001). No significant correlation between prostate SUVmax, SUVmean and age, the maximum transverse diameter of the prostate (r=0.047, 0.071, 0.040, 0.035, all P>0.05). Prostate CTmean increased with age, and an extremely weak correlation or no correlation was observed between them (r=0.126, P=0.091). The maximum transverse diameters of all the age groups (19–39, 40–59, 60–79, and 80–99 years) were (4.04±0.27), (4.52±0.53), (4.77±0.54), and (5.24±0.65) cm, respectively, the SUVmax were 2.48±0.65, 2.38±0.50, 2.46±0.47, 2.48±0.42, respetively; the SUVmean were 2.03±0.51, 1.90±0.44, 2.00±0.42, and 2.05±0.41, respectively; and the CTmean were (33.25±3.59), (34.19±3.76), (34.76±3.80), and (35.29±2.97) HU, respectively. Significant differences were found among the maximum transverse diameters of the age groups (F=16.278, P<0.001), whereas no significant difference was found among SUVmax, SUVmean, and CTmean. Conclusion The maximum transverse diameter of the prostate increases with age, but age does not significantly affect the glucose metabolism and CT density of the prostate. -
表 1 181例非前列腺癌患者的18F-FDG PET/CT参数及患者 年龄的相关性分析
Table 1. Correlation analysis among 18F-FDG PET/CT parameters, and patient age of 181 non prostate cancer
因变量 自变量 截距 斜率 r值 P值 最大横径 年龄 3.52 0.019 0.465 0.000 SUVmax 年龄 2.34 0.002 0.047 0.534 SUVmean 年龄 1.85 0.002 0.071 0.344 CTmean 年龄 32.53 0.032 0.126 0.091 SUVmax 最大横径 2.28 0.033 0.040 0.591 SUVmean 最大横径 1.86 0.026 0.035 0.644 CTmean 最大横径 33.97 0.111 0.018 0.814 SUVmean CTmean 2.13 −0.004 −0.038 0.612 注:表中,FDG:氟脱氧葡萄糖;PET:正电子发射断层显像术;CT:计算机体层摄影术;SUVmax:最大标准化摄取值;SUVmean:平均标准化摄取值;CTmean:平均CT值 表 2 181例不同年龄段非前列腺癌患者的18F-FDG PET/CT 的参数比较(
)$\bar x \pm s $ Table 2. Comparison of 18F-FDG PET/CT parameters of 181 non prostate cancer in all age groups (
)$\bar x \pm s $ 年龄段 例数 最大横径(cm) SUVmax SUVmean CTmean (HU) 19~39岁 16 4.04±0.27 2.48±0.65 2.03±0.51 33.25±3.59 40~59岁 57 4.52±0.53 2.38±0.50 1.90±0.44 34.19±3.76 60~79岁 94 4.77±0.54 2.46±0.47 2.00±0.42 34.76±3.80 80~99岁 14 5.24±0.65 2.48±0.42 2.05±0.41 35.29±2.97 F值 16.278 0.485 1.114 1.025 P值 0.000 0.693 0.345 0.383 LSD-t值 3.106 0.352 0.835 0.933 P值 0.001 0.772 0.442 0.355 注:表中,FDG:氟脱氧葡萄糖;PET:正电子发射断层显像术;CT:计算机体层摄影术;SUVmax:最大标准化摄取值;SUVmean:平均标准化摄取值;CTmean:平均CT值 -
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7−30. DOI: 10.3322/caac.21387. [2] Algaba F, Trias I, Arce Y. Natural history of prostatic carcinoma: the pathologist's perspective[J]. Recent Results Cancer Res, 2007, 175: 9−24. DOI: 10.1007/978-3-540-40901-4_2. [3] Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer[J]. Jpn J Clin Oncol, 1999, 29(12): 623−629. DOI: 10.1093/jjco/29.12.623. [4] Agus DB, Golde DW, Sgouros G, et al. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal[J]. Cancer Res, 1998, 58(14): 3009−3014. [5] 王治国, 郭佳, 石庆学, 等. 18F-FDG PET/CT在前列腺癌诊断中的应用价值[J]. 临床军医杂志, 2014, 42(4): 409−411. DOI: 10.3969/j.issn.1671-3826.2014.04.26.
Wang ZG, Guo J, Shi QX, et al. Value of 18F-FDG PET/CT in diagnosis of prostate cancer[J]. Clin J Med Offic, 2014, 42(4): 409−411. DOI: 10.3969/j.issn.1671-3826.2014.04.26.[6] 林美福, 周硕, 陈文新, 等. 18F-FDG、18F-FECH双示踪剂PET/CT在前列腺癌诊疗中的应用[J]. 福建医科大学学报, 2012, 46(5): 366−369. DOI: 10.3969/j.issn.1672-4194.2012.05.019.
Lin MF, Zhou S, Chen WX, et al. The clinical value of dual agents PET/CT in the diagnosis and treatment of prostate cancer using 18F-FDG and 18F-FECH[J]. J Fujian Med Univ, 2012, 46(5): 366−369. DOI: 10.3969/j.issn.1672-4194.2012.05.019.[7] Yang ZY, Hu SL, Cheng JY, et al. Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography[J]. Clin Imaging, 2014, 38(4): 470−474. DOI: 10.1016/j.clinimag.2014.01.019. [8] Takahashi N, Inoue T, Lee J, et al. The roles of PET and PET/CT in the diagnosis and management of prostate cancer[J]. Oncology, 2007, 72(3/4): 226−233. DOI: 10.1159/000112946. [9] Makis W, Ciarallo A. Clinical significance of 18F-Fluorodeoxyglucose avid prostate gland incidentalomas on positron emission tomography/computed tomography[J]. Mol Imaging Radionucl Ther, 2017, 26(2): 76−82. DOI: 10.4274/mirt.07769. [10] Pietrzak A, Czepczynski R, Wierzchoslawska E, et al. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by 18F-FDG PET/CT. The role of 99mTc-MDP[J]. Hell J Nucl Med, 2017, 20(3): 237−240. DOI: 10.1967/s002449910608. [11] Jadvar H, Velez EM, Desai B, et al. Prediction of time to hormonal treatment failure in metastatic castration-sensitive prostate cancer with 18F-FDG PET/CT[J]. J Nucl Med, 2019, 60(11): 1524−1530. DOI: 10.2967/jnumed.118.223263. [12] Wang YB, Chiu E, Rosenberg J, et al. Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues[J]. Mol Imaging Biol, 2007, 9(2): 83−90. DOI: 10.1007/s11307-006-0075-y. [13] Jadvar H, Ye W, Groshen S, et al. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland[J]. Ann Nucl Med, 2008, 22(9): 787−793. DOI: 10.1007/s12149-008-0177-5. [14] Well D, Yang H, Houseni M, et al. Age-related structural and metabolic changes in the pelvic reproductive end organs[J]. Semin Nucl Med, 2007, 37(3): 173−184. DOI: 10.1053/j.semnuclmed.2007.01.004. [15] Britt RH, Lyons BE, Enzmann DR, et al. Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors[J]. J Neurooncol, 1987, 4(3): 243−268. DOI: 10.1007/BF00150616. [16] Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor microenvironment[J]. Int J Radiat Oncol Biol Phys, 2005, 62(2): 545−553. DOI: 10.1016/j.ijrobp.2005.02.009.